Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study.
COVID-19
Hematological malignancies
SARS-CoV-2
Solid tumor
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
28
08
2020
accepted:
24
03
2021
pubmed:
15
4
2021
medline:
16
10
2021
entrez:
14
4
2021
Statut:
ppublish
Résumé
Immunocompromised cancer patients are presumed to be at high risk of developing COVID-19 infection. Predisposing factors to contracting COVID-19 and to severe outcomes have been described in registries but were not compared between solid tumors and hematological malignancies. This retrospective single oncologic center study included adults with solid tumors or hematological malignancies referred to testing by naso-pharyngeal swab for a SARS-CoV-2 RT-PCR from March 10 to May 18, 2020. A total of 212 patients were included in the study. Forty-five (21%) were tested positive with SARS-CoV-2. The univariate analysis with positive SARS-CoV-2 PCR as a dependent variable reveals significant odds ratios (ORs) for age-with a mean of 62.5 years-(OR: 1.05, 95% CI: 1.02-1.08), performance status ≥2 (OR: 2.38, 95% CI: 1.22-4.70), inpatient status (OR: 2.36, 95%CI: 1.11-4.91), and hematological malignancies (OR: 2.48, 95% CI: 1.23-4.96). In contrast, OR for solid tumors reveals a negative association (OR: 0.40, 95% CI: 0.20-0.81). When integrating severe outcome (ICU admission or COVID-19-related death) as a dependent variable, the univariate logistic regression model shows significant ORs for pre-existing lymphopenia (OR: 4.0, 95% CI: 1.17-15.04), hematological malignancies (OR: 3.73, 95% CI: 1.09-13.80), and a negative association for solid tumors (OR: 0.27; 95% CI: 0.07-0.92). In patients referred for SARS-CoV-2 testing, hematological malignancies were associated with a higher risk of COVID-19 infection and severe outcomes. Other factors were age and inpatient status.
Sections du résumé
BACKGROUND
BACKGROUND
Immunocompromised cancer patients are presumed to be at high risk of developing COVID-19 infection. Predisposing factors to contracting COVID-19 and to severe outcomes have been described in registries but were not compared between solid tumors and hematological malignancies.
METHOD
METHODS
This retrospective single oncologic center study included adults with solid tumors or hematological malignancies referred to testing by naso-pharyngeal swab for a SARS-CoV-2 RT-PCR from March 10 to May 18, 2020.
RESULTS
RESULTS
A total of 212 patients were included in the study. Forty-five (21%) were tested positive with SARS-CoV-2. The univariate analysis with positive SARS-CoV-2 PCR as a dependent variable reveals significant odds ratios (ORs) for age-with a mean of 62.5 years-(OR: 1.05, 95% CI: 1.02-1.08), performance status ≥2 (OR: 2.38, 95% CI: 1.22-4.70), inpatient status (OR: 2.36, 95%CI: 1.11-4.91), and hematological malignancies (OR: 2.48, 95% CI: 1.23-4.96). In contrast, OR for solid tumors reveals a negative association (OR: 0.40, 95% CI: 0.20-0.81). When integrating severe outcome (ICU admission or COVID-19-related death) as a dependent variable, the univariate logistic regression model shows significant ORs for pre-existing lymphopenia (OR: 4.0, 95% CI: 1.17-15.04), hematological malignancies (OR: 3.73, 95% CI: 1.09-13.80), and a negative association for solid tumors (OR: 0.27; 95% CI: 0.07-0.92).
CONCLUSION
CONCLUSIONS
In patients referred for SARS-CoV-2 testing, hematological malignancies were associated with a higher risk of COVID-19 infection and severe outcomes. Other factors were age and inpatient status.
Identifiants
pubmed: 33851236
doi: 10.1007/s00520-021-06175-z
pii: 10.1007/s00520-021-06175-z
pmc: PMC8043836
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6271-6278Informations de copyright
© 2021. The Author(s).
Références
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
Front Microbiol. 2018 Dec 12;9:3097
pubmed: 30619176
Leukemia. 2020 Jun;34(6):1637-1645
pubmed: 32332856
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
JCO Glob Oncol. 2020 Jun;6:799-808
pubmed: 32511066
J Hematol Oncol. 2020 Jun 10;13(1):75
pubmed: 32522278
Lancet Oncol. 2020 Jul;21(7):904-913
pubmed: 32479787
Immunotherapy. 2020 Apr;12(5):269-273
pubmed: 32212881
JCO Glob Oncol. 2020 Apr;6:557-559
pubmed: 32250659
Am J Med. 1997 Mar 17;102(3A):10-8; discussion 25-6
pubmed: 10868137
Rev Infect Dis. 1989 Nov-Dec;11(6):954-63
pubmed: 2690289
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Cardiovasc Res. 2020 Aug 1;116(10):1666-1687
pubmed: 32352535
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088